Ask about this productRelated genes to: MRPL23 antibody
- Gene:
- MRPL23 NIH gene
- Name:
- mitochondrial ribosomal protein L23
- Previous symbol:
- RPL23L
- Synonyms:
- L23MRP
- Chromosome:
- 11p15.5
- Locus Type:
- gene with protein product
- Date approved:
- 1996-05-15
- Date modifiied:
- 2015-08-25
Related products to: MRPL23 antibody
Related articles to: MRPL23 antibody
- Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Despite advances in therapy, survival remains poor due to late diagnosis and treatment resistance. Identification of reliable prognostic biomarkers is essential to improve risk stratification and clinical outcomes. - Source: PubMed
Publication date: 2026/02/02
Podemska EdytaGostomczyk KarolJerka DominikaBorowczak JędrzejGagat MaciejGrzanka DariuszDurślewicz Justyna - Prostate cancer (PCa) is the fourth most commonly diagnosed malignancy worldwide and remains a major clinical challenge due to its heterogeneous course and lack of reliable prognostic biomarkers. Mitochondrial ribosomal protein L23 (MRPL23) has recently emerged as a potential contributor to cancer progression, but its role in prostate cancer remains poorly understood. Formalin-fixed, paraffin-embedded (FFPE) tissue samples from 67 PCa patients who underwent radical prostatectomy were analyzed. MRPL23 expression was assessed by immunohistochemistry using a semi-quantitative immunoreactive scale (IRS). Clinicopathological data were collected for correlation analysis. Survival outcomes were evaluated using Kaplan-Meier curves and Cox proportional hazards models. MRPL23 expression differed significantly across all tissue types, with higher levels in prostate cancer tissues compared with normal epithelium, and the highest expression observed in lymph node metastases (P < .001). High MRPL23 expression was associated with shorter overall survival (P = .003) and remained an independent prognostic factor in the multivariate analysis (HR 3.99, 95% CI 1.63-9.77, P = .002). Complementary TCGA analysis confirmed elevated MRPL23 mRNA levels in prostate adenocarcinomas compared with normal tissues (P = .01) and demonstrated that high expression predicted shorter disease-free survival (10-year DFS: 75.98% versus 92.92%, log-rank P = .01). MRPL23 is a potential prognostic biomarker in prostate cancer, linked to aggressive tumor behavior and poor outcomes. Its expression in metastatic tissue suggests a role in disease progression, while TCGA data confirm its prognostic value for recurrence risk. MRPL23 may also serve as a therapeutic target in advanced PCa. - Source: PubMed
Podemska EdytaŁukasik DamianBorowczak JędrzejGrzanka DariuszDurślewicz Justyna - Hepatocellular carcinoma (HCC) is the most common form of liver cancer and remains a global health challenge. The biological process of HCC is very complex, involving the imbalance of tumor suppressor genes and oncogenes, abnormal activation of molecular signaling pathways, and the differentiation of HCC cells. Standard clinical approaches for HCC treatment encompass surgery, chemotherapy, and radiation therapy. However, treatment options for advanced HCC are constrained, primarily due to an incomplete understanding of its underlying mechanisms. Cellular senescence is a crucial mechanism that influences the pathophysiological processes of HCC and serves as a potent barrier to tumor development. Our research identified the biological functions and mechanisms of Mitochondrial Ribosomal Protein L23 (MRPL23) in relation to cellular senescence in HCC. Results demonstrated that MRPL23 was upregulated in both tumor tissues and hepatoma cells. Additionally, the inhibition of MRPL23 resulted in decreased cell proliferation and promoted cellular senescence. Moreover, MRPL23 deficiency protected against HCC progression in a mouse model. Finally, we confirmed that MRPL23 regulated cellular senescence by targeting HMGB1 using the inhibitor NecroX-7. These findings laid the foundation for developing potential therapies for HCC by inhibiting MRPL23 or inducing senescence. - Source: PubMed
Publication date: 2025/06/09
Huang Ya-BinXu Shi-MengLi MinChen JinLu Cui-HuaLiu Qing-Qing - Retinal vessel caliber is strongly associated with systemic blood pressure (BP); however, the causal relationship between retinal vascular caliber and BP remains unclear. Understanding this relationship is essential for advancing predictive, preventive, and personalized medicine (PPPM) approaches to effectively manage hypertension and its related complications. - Source: PubMed
Publication date: 2025/05/06
Niu YongyiLi XueGuo JingzeLuo SongyuanShang XianwenLiu JingLiu ShunmingHe MingguangShi DanliHuang YuZhang Hongyang - The prognostic factors at mutational and transcriptional levels are not clear for stage IV colorectal cancer (CRC) patients with liver metastasis who undergo primary cancer palliative surgery with post-surgical adjuvant therapy. We aimed to establish and validate models for predicting the prognosis of these patients by combining mutational, transcriptional and clinicopathological information. - Source: PubMed
Publication date: 2025/01/21
Shen SijiaZhang Xu